

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/989,388	11/21/2001	Wataru Morikawa	MORIKAWA4A 1349	
7590 03/23/2006			EXAMINER	
BROWDY AND NEIMARK. P.L.L.C.			HARRIS, ALANA M	
ATTORNEYS AT LAW SUITE 300			ART UNIT	PAPER NUMBER
624 NINTH STREET, N.W.			1643	
WASHINGTON, DC 20001-5303			DATE MAILED: 03/23/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	09/989,388	MORIKAWA ET AL.			
Office Action Summary	Examiner	Art Unit			
	Alana M. Harris, Ph.D.	1643			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period was realized to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from 1, cause the application to become ABANDONEI	I. lely filed the mailing date of this communication. O (35 U.S.C. § 133).			
Status					
Responsive to communication(s) filed on <u>27 December</u> 2a) This action is FINAL . 2b) This 3) Since this application is in condition for alloware closed in accordance with the practice under E	action is non-final. nce except for formal matters, pro				
Disposition of Claims					
4) ⊠ Claim(s) <u>1-4</u> is/are pending in the application. 4a) Of the above claim(s) is/are withdrav 5) □ Claim(s) is/are allowed. 6) ☒ Claim(s) <u>1-4</u> is/are rejected. 7) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction and/or					
Application Papers					
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the objected to by the Examine 10) The oath or declaration is objected to by the Examine	epted or b) objected to by the bedrawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:				

Application/Control Number: 09/989,388 Page 2

Art Unit: 1643

DETAILED ACTION

Request for Continued Examination

- 1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on December 27, 2005 has been entered.
- Claims 1-4 are pending.
 - Claims 1, 2 and 3 have been amended.
 - Claims 1-4 are examined on the merits.

Withdrawn Rejection

Claim Rejections - 35 USC § 102

3. The rejection of claims 1-4 under 35 U.S.C. 102(b) as being anticipated by U.S. Patent number 5,288,489 (February 22, 1994/ IDS reference AA) is withdrawn in light of Applicants' amendment to the claims and Applicants' arguments.

Claim Rejections - 35 USC § 103

- 4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and

Application/Control Number: 09/989,388

Art Unit: 1643

the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

5. Claims 1-4 are rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent number 5,288,489 (February 22, 1994/ IDS reference AA), and further in view of U.S. Patent number 6,566,098 B1 (filed June 7, 1995).

The patent teaches "...a fragment consisting of the proenzyme domain of plasminogen with a single attached kringle is generated, the remaining 4 kringles and intervening peptides having been separated.", see column 8, lines 52-58. The recovered fragment encompasses the Lys-Lysine binding site I, see column 8, lines 47-65. Patent '489 does not teach the fragments have been subjected to heparin affinity chromatography for selecting heparin-binding fractions.

However, U.S. Patent number 6,566,098 teaches a one-step purification process of hepatocyte growth factor (HGF) based on heparin affinity chromatography. "HGF resembles plasminogen in that it possesses characteristic kringle domains.", see column 1, lines 42-48; and column 7, lines 17-26. It would have been *prima facie* obvious to one of ordinary skill in the art at the time of the claimed invention was made to implement this mode of separating kringle fragments. The separation in itself implies fractions of fragments were generated and these fractions of fragments would bind heparin. One of ordinary skill in the art would have been motivated to do so with a reasonable expectation of success by teachings in both patents to fractionate plasminogen of patent '489 in order to arrive at active fragments of the molecule for therapeutic use, as well as to further define the molecule for therapeutic, enzymatic and

or catalytic activity, see Patent '489, bridging paragraph of columns 2 and 3; columns 10-14: Patent '098, see column 7, lines 34-60; column 32, lines 9-28.

Page 4

It still remains that the starting material of patent '489 is the same as Applicants' and the same mode of separation would yield the same product of Applicants'. The products of identical chemical composition cannot have mutually exclusive properties. A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present. In re Spada 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). See MPEP 2112.01.

6. Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Alana M. Harris, Ph.D. whose telephone number is (571) 272-0831. The Examiner works a flexible schedule, however she can normally be reached between the hours of 7:30 am to 6:30 pm with alternate Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Larry R. Helms, Ph.D. can be reached on (571) 272-0832. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 09/989,388 Page 5

Art Unit: 1643

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

ALANA M. HARRIS, PH.D. PRIMARY EXAMINER

Alana M. Harris, Ph.D.

16 March 2006